Table 4.

Secondary Outcomes over 9-months in both active treatment groups

	Baseline			3-Month			6-Month			9-Month
	N	Mean (SD)	p-value	N	Mean (SD)	p-value	N	Mean (SD)	p-value	N	Mean (SD)	p-value
HAQ Score (0–3; lower=better)
Cherry extract	41	0.58 (0.71)	0.57	41	0.21 (0.38)	0.75	37	0.21 (0.42)	0.66	32	0.20 (0.40)	0.90
Diet modification	43	0.49 (0.60)		37	0.18 (0.29)		31	0.17 (0.31)		26	0.18 (0.36)
Proportion with HAQ MCID1
Cherry extract		N/A		41	58.5%	0.82	37	64.9%	0.22	32	59.4%	0.79
Diet modification		N.A		37	54.1%		31	48.4%		26	53.9%
Maximum Pain in last 24 hrs, 0–10
Cherry extract	41	2.83 (3.07)	0.34	41	1.46 (2.47)	0.65	37	1.30 (2.31)	0.81	32	1.16 (2.27)	0.62
Diet modification	43	2.11 (2.89)		37	1.24 (1.72)		31	1.16 (2.34)		26	0.88 (1.77)
Any adverse event, %
Cherry extract		N/A		40	2.5	1.00	37	8.1	0.25	32	3.1	1.00
Diet modification		N/A		35	0.0		30	0.0		26	0.0
Specific gastrointestinal adverse event, %
Cherry extract		N/A		41	31.7	0.81	37	32.4	0.80	32	28.1	1.00
Diet modification		N/A		37	35.1		31	35.5		26	26.9

¹HAQ MCID: HAQ score reduction of 0.22 or more during FU

N/A: not applicable